Molecular theory of cancer

The mutation theory of cancer was always challenged by alternative (vitalistic) theories, which insist that cancer (like life itself) cannot be reduced to molecular interactions. In fact, the most fundamental feature of the somatic mutation theory of cancer is that it is a molecular theory, meaning that all the complexity of cancer on any level (e.g., tissue) can be explained on the molecular level. To emphasize the essence of mutation theory, cancer-causing mutation can be defined as any (a) molecular event that is (b) somatically-inheritable and (c) selectable (e.g., provides selective advantage in restrictive/carcinogenic conditions). Here I review molecular (somatic mutation) theory and its alternatives and discuss that molecular interactions can completely explain complex tissue phenomena such as benign tumors and stroma-initiated tumorigenesis. In addition, molecular theory predicts extragenetic somatic hereditary in cancer (e.g., posttranslational protein modifications that initiate and are supported by positive feedback loops) and also explains the relationship between selection for resistance, hallmarks of cancer and genetic instability. From molecules to cells to organism, this review discusses how somatically-heritable molecular alterations (genetic, epigenetic and extragenetic) alter translation of cellular signals, resulting in resistance to growth inhibition and apoptosis, that is manifested as secondary hallmarks of cancer (metastases, angiogenesis and immortality) and, finally, as the amazing ability of some cancer cells such as canine transmissible sarcoma to ‘live in a wild’ like unicellular mammalian species.

[1]  Keiji Suzuki,et al.  Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. , 2001, Cancer research.

[2]  G. Semenza,et al.  Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.

[3]  F. Taddei,et al.  Costs and Benefits of High Mutation Rates: Adaptive Evolution of Bacteria in the Mouse Gut , 2001, Science.

[4]  W. El-Deiry,et al.  Cell cycle checkpoint control mechanisms that can be disrupted in cancer. , 2004, Methods in molecular biology.

[5]  R. Kerbel,et al.  Contrasting effects of VEGF gene disruption in embryonic stem cell‐derived versus oncogene‐induced tumors , 2003, The EMBO journal.

[6]  D. Cohen.  The canine transmissible venereal tumor: a unique result of tumor progression. , 1985, Advances in cancer research.

[7]  T. J. Yang,et al.  Role of humoral immunity in progressive and regressive and metastatic growth of the canine transmissible venereal sarcoma. , 1988, Oncology.

[8]  P. Duesberg,et al.  Aneuploidy Approaching a Perfect Score in Predicting and Preventing Cancer: Highlights from a Conference Held in Oakland, CA in January, 2004 , 2004, Cell cycle.

[9]  Jiri Bartek,et al.  Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.

[10]  J. Masters.  HeLa cells 50 years on: the good, the bad and the ugly , 2002, Nature Reviews Cancer.

[11]  K. Nose,et al.  Invasive Potential Induced under Long-Term Oxidative Stress in Mammary Epithelial Cells , 2004, Cancer Research.

[12]  C. Sonnenschein,et al.  Somatic mutation theory of carcinogenesis: Why it should be dropped and replaced , 2000, Molecular carcinogenesis.

[13]  R. Weinberg,et al.  Specific growth response of ras-transformed embryo fibroblasts to tumour promoters , 1985, Nature.

[14]  P. Chiao,et al.  Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. , 2004, The Journal of biological chemistry.

[15]  Mikhail V. Blagosklonny,et al.  The Restriction Point of the Cell Cycle , 2002, Cell cycle.

[16]  Kengo Morimoto,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[17]  R. Schulte‐Hermann,et al.  Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. , 2002, Journal of cell science.

[18]  R. Cardell,et al.  Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the myc protooncogene. , 1991, The American journal of pathology.

[19]  M. Kasper,et al.  Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma , 2002, Oncogene.

[20]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[21]  A. Schulze,et al.  Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. , 2000, Genes & development.

[22]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[23]  A. Pardee,et al.  Regulation in S Phase by E2F , 2004, Cell cycle.

[24]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[25]  K. Liao,et al.  Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically toxic for B cells. , 2003, Veterinary immunology and immunopathology.

[26]  B. Druker.  Imatinib: Paradigm or Anomaly? , 2004, Cell cycle.

[27]  C. Morrison,et al.  Combined Total Genome Loss of Heterozygosity Scan of Breast Cancer Stroma and Epithelium Reveals Multiplicity of Stromal Targets , 2004, Cancer Research.

[28]  M. Barcellos-Hoff,et al.  Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. , 2000, Cancer research.

[29]  J. Redpath,et al.  Reversion of UVC-induced tumorigenic human hybrid cells to the non-tumorigenic phenotype. , 1996, European journal of cancer.

[30]  S. Holt,et al.  Resistance to apoptosis in human cells conferred by telomerase function and telomere stability , 1999, Molecular carcinogenesis.

[31]  N. Ahn,et al.  Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. , 2000, Cancer Research.

[32]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[33]  C. Klein,et al.  Gene Expression Signatures, Cancer Cell Evolution and Metastatic Progression , 2004, Cell cycle.

[34]  M. Sporn,et al.  Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor , 1986, Molecular and cellular biology.

[35]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[36]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.

[37]  A. Mercurio,et al.  Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. , 2003, Molecular biology of the cell.

[38]  P. Dhawan,et al.  Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer research.

[39]  I. Roninson,et al.  Induction of senescence‐associated growth inhibitors in the tumor‐suppressive function of retinoids , 2003, Journal of cellular biochemistry.

[40]  M. Zollo,et al.  Unraveling Genes and Pathways Influenced by H-Prune PDE Overexpression: A Model to Study Cellular Motility , 2004, Cell cycle.

[41]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[42]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[43]  G. Neufeld,et al.  Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  R. Albertini,et al.  Emergence of genetic instability in children treated for leukemia. , 2000, Science.

[45]  R. Kerbel,et al.  Ras regulation of vascular endothelial growth factor and angiogenesis. , 2001, Methods in enzymology.

[46]  D. Schaffer,et al.  The sonic hedgehog signaling system as a bistable genetic switch. , 2004, Biophysical journal.

[47]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[48]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[49]  J. Massagué,et al.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.

[50]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[51]  J. Campisi,et al.  Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation , 2004, Journal of Cell Science.

[52]  H. Wallenburg,et al.  Choriocarcinoma with lung metastases during pregnancy with successful delivery and outcome after chemotherapy. , 1990, Thorax.

[53]  W. Hahn,et al.  Derivation of human tumor cells in vitro without widespread genomic instability. , 2001, Cancer research.

[54]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[55]  R. Assoian,et al.  Integrating the MAP kinase signal into the G1 phase cell cycle machinery. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[56]  M. Blagosklonny.  Cell Immortality and Hallmarks of Cancer , 2003, Cell cycle.

[57]  L. J. Veer,et al.  Hard Wired Genotype in Metastatic Breast Cancer , 2004, Cell cycle.

[58]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[59]  Martin A. Nowak,et al.  The significance of unstable chromosomes in colorectal cancer , 2003, Nature Reviews Cancer.

[60]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[61]  A. Hakura,et al.  An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis. , 1995, Oncogene.

[62]  D. Lauffenburger,et al.  Autocrine loops with positive feedback enable context-dependent cell signaling. , 2002, American journal of physiology. Cell physiology.

[63]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[64]  D. Chopin,et al.  Epithelial Cell Plasticity in Development and Tumor Progression , 2004, Cancer and Metastasis Reviews.

[65]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[66]  A. Gudkov,et al.  Paradoxical role of apoptosis in tumor progression , 2003, Journal of cellular biochemistry.

[67]  P. Chiao,et al.  Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1α in Induction of Constitutive NF-κB Activation in Pancreatic Cancer Cells* , 2004, Journal of Biological Chemistry.

[68]  S. Yagel,et al.  Normal nonmetastatic human trophoblast cells share in vitro invasive properties of malignant cells , 1988, Journal of cellular physiology.

[69]  Armand M. Leroi,et al.  Cancer selection , 2003, Nature Reviews Cancer.

[70]  T. Whiteside,et al.  Activation of Raf by ionizing radiation , 1996, Nature.

[71]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.

[72]  R. Weinberg.  E2F and Cell Proliferation: A World Turned Upside Down , 1996, Cell.

[73]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[74]  R. Schmidt-Ullrich,et al.  Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1 , 2003, Radiation research.

[75]  M. Blagosklonny.  How Cancer Could be Cured by 2015 , 2005, Cell cycle.

[76]  A. Feinberg,et al.  Epigenetic variability and the evolution of human cancer. , 2003, Advances in cancer research.

[77]  A Sewing,et al.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[78]  P. Verde,et al.  Accumulation of Fra-1 in ras-Transformed Cells Depends on Both Transcriptional Autoregulation and MEK-Dependent Posttranslational Stabilization , 2003, Molecular and Cellular Biology.

[79]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[80]  A. Pardee.  PaJaMas in Paris. , 2002, Trends in genetics : TIG.

[81]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[82]  W. Hahn,et al.  Immortalization and transformation of primary human airway epithelial cells by gene transfer , 2002, Oncogene.

[83]  M. Nowak,et al.  Dynamics of Genetic Instability in Sporadic and Familial Colorectal Cancer , 2002, Cancer biology & therapy.

[84]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[85]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[86]  I. Roninson.  Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. , 2002, Cancer letters.

[87]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[88]  M. Karin,et al.  Three distinct signalling responses by murine fibroblasts to genotoxic stress , 1996, Nature.

[89]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[90]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[91]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[92]  L. Einhorn.  Curing metastatic testicular cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Valeria Souza,et al.  Stress-Induced Mutagenesis in Bacteria , 2003, Science.

[94]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[95]  R. Kerbel,et al.  Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? , 1994, Journal of cellular biochemistry.

[96]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[97]  E. Lees,et al.  Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[98]  M. Blagosklonny.  Apoptosis, proliferation, differentiation: in search of the order. , 2003, Seminars in cancer biology.

[99]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[100]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[101]  T. Herzog,et al.  Gestational trophoblastic diseases: new standards for therapy , 2000, Current opinion in oncology.

[102]  John Calvin Reed.  Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[103]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[104]  D. C. Malins,et al.  Metastasizing and Non-Metastasizing Tumors Likely Evolve from DNA Phenotypes via Independent Pathways , 2004, Cell cycle.

[105]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[106]  C. Logothetis,et al.  Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  F E Cohen,et al.  Pathologic conformations of prion proteins. , 1998, Annual review of biochemistry.

[108]  I. Roninson,et al.  If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[109]  L. Wakefield,et al.  TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.

[110]  K. Kinzler,et al.  Carcinogen-specific induction of genetic instability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[111]  C. Stackpole,et al.  Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. , 1994, Journal of the National Cancer Institute.

[112]  M. Blagosklonny.  Oncogenic resistance to growth-limiting conditions , 2002, Nature Reviews Cancer.

[113]  Robert Longtin,et al.  For tissue organization theory of cancer, a difficult road to acceptance. , 2005, Journal of the National Cancer Institute.

[114]  R. Cripps,et al.  Positive autoregulation of the Myocyte enhancer factor-2 myogenic control gene during somatic muscle development in Drosophila. , 2004, Developmental biology.

[115]  M. Blagosklonny.  Cell senescence and hypermitogenic arrest , 2003, EMBO reports.